Vanda Pharmaceuticals Investor Relations Material
Latest events
Q2 2025
Vanda Pharmaceuticals
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Vanda Pharmaceuticals Inc
Access all reports
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ (tasimelteon) for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone) for the treatment of bipolar disorder. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder and smith-magenis syndrome; Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness; Fanapt oral tablets for the treatment of schizophrenia; Novel fixed dose combination products: anoro progesterone vaginal system/norethindrone acetate tablets in women
Latest articles
)
Global Doughmination: Breaking Down Domino's Pizza
Inside the rise of Domino's Pizza: how franchising, delivery control, and supply chain mastery built one of the world's most efficient food empires.
18 Jul 2025
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
Ticker symbol
VNDA
Country
🇺🇸 United States